Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Top Cited Papers
Open Access
- 10 August 2017
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (2), 1700050
- https://doi.org/10.1183/13993003.00050-2017
Abstract
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event. Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI–ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies. We identified 64 (3.5%) out of 1826 cancer patients with ICI–ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2−27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7–73.8%). ICI–ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event. Awareness of clinical/radiological presentation of immunotherapy-related pneumonitis is crucial to ensure a diagnosishttp://ow.ly/eIMF30bgolfKeywords
This publication has 38 references indexed in Scilit:
- PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical CourseClinical Cancer Research, 2016
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinomaLung Cancer, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Anti–PD-1–Related Pneumonitis during Cancer ImmunotherapyThe New England Journal of Medicine, 2015
- Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findingsInternational Journal of Clinical Oncology, 2012
- Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?Chemotherapy, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosisInternational Journal of Radiation Oncology*Biology*Physics, 2001